| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,287 |
3,008 |
$2.44M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
6,497 |
5,900 |
$1.78M |
| G0378 |
Hospital observation service, per hour |
1,829 |
1,536 |
$1.53M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
6,199 |
5,530 |
$1.36M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,387 |
1,264 |
$979K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
2,574 |
2,411 |
$728K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,473 |
2,303 |
$472K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,373 |
1,296 |
$367K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
513 |
483 |
$323K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,723 |
1,557 |
$262K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
5,059 |
3,255 |
$231K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
361 |
348 |
$146K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
28 |
26 |
$81K |
| A4649 |
Surgical supply; miscellaneous |
1,171 |
1,081 |
$49K |
| 83880 |
|
2,994 |
2,707 |
$30K |
| 71046 |
Radiologic examination, chest; 2 views |
1,348 |
1,299 |
$27K |
| 80053 |
Comprehensive metabolic panel |
1,610 |
1,352 |
$23K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
2,386 |
1,134 |
$15K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
205 |
201 |
$15K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
136 |
127 |
$14K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
90 |
90 |
$10K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
3,995 |
3,197 |
$8K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
8,169 |
6,920 |
$8K |
| 87040 |
|
3,751 |
2,231 |
$5K |
| 87631 |
|
2,220 |
1,998 |
$4K |
| 72100 |
|
215 |
205 |
$4K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
9,653 |
7,104 |
$3K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
69 |
64 |
$3K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
15 |
15 |
$3K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
1,498 |
921 |
$2K |
| 71045 |
Radiologic examination, chest; single view |
6,157 |
5,526 |
$2K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
2,923 |
2,690 |
$2K |
| 83605 |
|
4,337 |
3,888 |
$2K |
| 80306 |
|
1,713 |
1,606 |
$2K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
802 |
769 |
$2K |
| 73560 |
|
214 |
203 |
$1K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
1,315 |
1,210 |
$954.82 |
| 96367 |
|
534 |
404 |
$755.82 |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
20 |
16 |
$755.20 |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
1,355 |
1,278 |
$642.54 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
3,443 |
2,745 |
$573.55 |
| 73130 |
|
29 |
26 |
$555.62 |
| 85730 |
|
2,253 |
2,077 |
$343.94 |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
13,654 |
10,125 |
$302.19 |
| 73610 |
|
13 |
13 |
$264.83 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
820 |
739 |
$203.39 |
| 93017 |
|
26 |
24 |
$170.50 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
3,820 |
2,050 |
$155.13 |
| 73630 |
|
29 |
27 |
$146.59 |
| 73030 |
|
54 |
50 |
$134.77 |
| A9270 |
Non-covered item or service |
21,277 |
2,812 |
$86.66 |
| 96160 |
|
528 |
463 |
$57.02 |
| 84443 |
Thyroid stimulating hormone (TSH) |
377 |
348 |
$55.79 |
| 90715 |
|
111 |
107 |
$38.75 |
| 81001 |
|
5,858 |
5,375 |
$25.16 |
| 83690 |
|
3,769 |
3,446 |
$18.24 |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,306 |
1,221 |
$12.80 |
| 81025 |
|
751 |
695 |
$12.30 |
| 84484 |
|
6,067 |
4,959 |
$8.47 |
| 86850 |
|
37 |
27 |
$8.12 |
| 87186 |
|
885 |
829 |
$7.51 |
| 80076 |
|
3,966 |
3,537 |
$6.38 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,812 |
3,339 |
$6.00 |
| 83735 |
|
3,315 |
2,643 |
$5.96 |
| 82550 |
|
463 |
422 |
$5.79 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
106 |
102 |
$4.46 |
| 85610 |
|
4,404 |
3,985 |
$3.49 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,084 |
546 |
$1.18 |
| 82374 |
|
2,383 |
1,746 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
217 |
207 |
$0.00 |
| 84100 |
|
1,636 |
1,350 |
$0.00 |
| 82948 |
|
2,504 |
1,407 |
$0.00 |
| 82310 |
|
2,282 |
1,669 |
$0.00 |
| 82565 |
|
2,391 |
1,750 |
$0.00 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
2,805 |
2,501 |
$0.00 |
| 84460 |
|
886 |
756 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
450 |
396 |
$0.00 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
15 |
15 |
$0.00 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
506 |
442 |
$0.00 |
| 84295 |
|
2,391 |
1,751 |
$0.00 |
| J0689 |
Injection, cefazolin sodium (baxter), not therapeutically equivalent to j0690, 500 mg |
381 |
231 |
$0.00 |
| 88312 |
|
25 |
24 |
$0.00 |
| 97161 |
|
41 |
40 |
$0.00 |
| 82947 |
|
2,347 |
1,726 |
$0.00 |
| 82248 |
|
724 |
674 |
$0.00 |
| 84520 |
|
2,398 |
1,759 |
$0.00 |
| 84155 |
|
886 |
756 |
$0.00 |
| 84450 |
|
885 |
755 |
$0.00 |
| 82247 |
|
884 |
755 |
$0.00 |
| 99152 |
|
14 |
14 |
$0.00 |
| J0134 |
Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg |
113 |
82 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
40 |
32 |
$0.00 |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
90 |
79 |
$0.00 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
17 |
16 |
$0.00 |
| C9113 |
Injection, pantoprazole sodium, per vial |
21 |
12 |
$0.00 |
| 84145 |
|
76 |
70 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
16 |
12 |
$0.00 |
| Q0243 |
Injection, casirivimab and imdevimab, 2400 mg |
14 |
13 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
13 |
12 |
$0.00 |
| 86900 |
|
36 |
27 |
$0.00 |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
13 |
13 |
$0.00 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
12 |
12 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
1,469 |
1,148 |
$0.00 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,281 |
1,127 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
2,068 |
1,884 |
$0.00 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,700 |
1,557 |
$0.00 |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,309 |
879 |
$0.00 |
| 96376 |
|
1,281 |
691 |
$0.00 |
| J1815 |
Injection, insulin, per 5 units |
33 |
27 |
$0.00 |
| 84703 |
|
566 |
525 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
2,607 |
2,437 |
$0.00 |
| 84132 |
|
2,396 |
1,753 |
$0.00 |
| 82150 |
|
27 |
24 |
$0.00 |
| 82553 |
|
101 |
97 |
$0.00 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
282 |
249 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
3,393 |
2,854 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
173 |
145 |
$0.00 |
| 82040 |
|
887 |
757 |
$0.00 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
180 |
138 |
$0.00 |
| 87205 |
|
187 |
179 |
$0.00 |
| 88304 |
|
178 |
161 |
$0.00 |
| 82435 |
|
2,383 |
1,746 |
$0.00 |
| 87077 |
|
464 |
436 |
$0.00 |
| 86901 |
|
36 |
27 |
$0.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
51 |
51 |
$0.00 |
| J2060 |
Injection, lorazepam, 2 mg |
44 |
39 |
$0.00 |
| J3480 |
Injection, potassium chloride, per 2 meq |
49 |
25 |
$0.00 |
| 87070 |
|
112 |
107 |
$0.00 |
| P9612 |
Catheterization for collection of specimen, single patient, all places of service |
14 |
14 |
$0.00 |
| 87071 |
|
60 |
59 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
16 |
14 |
$0.00 |
| 87088 |
|
132 |
126 |
$0.00 |
| 84075 |
|
885 |
755 |
$0.00 |
| J1940 |
Injection, furosemide, up to 20 mg |
13 |
12 |
$0.00 |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
14 |
13 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
67 |
54 |
$0.00 |
| 94760 |
|
32 |
26 |
$0.00 |
| 80051 |
|
13 |
13 |
$0.00 |
| 97165 |
|
29 |
28 |
$0.00 |
| 85379 |
|
15 |
14 |
$0.00 |